About Lifordi

Lifordi is among the first companies to leverage the success of antibody-drug conjugates (ADC) in oncology to develop treatments for autoimmune and inflammatory disorders. We have demonstrated superior efficacy in multiple preclinical diseases models by targeting myeloid and lymphoid cells using a highly internalized cell surface membrane protein. As experienced drug developers with expertise in immunology and inflammatory diseases, a strong partnering track record, and funding from ARCH Venture Partners, 5AM Ventures, and Atlas Venture to support initial clinical data, we can change how immune and inflammatory diseases are treated.